BLAINJECTIONINJECTABLE
Approved
Apr 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Mechanism of Action
Tumor Necrosis Factor Receptor Blocking Activity
Pharmacologic Class:
Tumor Necrosis Factor Blocker
Clinical Trials (5)
Zymfentra (Infliximab-dyyb) REal World Cohort STudy
Started Nov 2025
Subcutaneous Infliximab After A Previous Intravenous Dose Optimization
Started Apr 2024
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Started Dec 2023
2,207 enrolled
Arthritis, RheumatoidColitis, UlcerativeCrohn Disease+1 more
Precise Infliximab Exposure and Pharmacodynamic Control
Started Jul 2023
180 enrolled
Crohn Disease
InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease
Started Nov 2021